Urology company Corinth MedTech stated on Friday that it has raised USD12m under its equity financing led by ShangBay Capital LLC,Aethan Capital Inc as well as existing investors.
Proceeds from the financing will be used by Corinth MedTech to launch the commercialisation of the Veloxion System, which received US Food and Drug Administration (FDA) 510(k) clearance, for the treatment of BPH (Benign Prostatic Hyperplasia) and TURBT (Transurethral Resection of Bladder Tumor).
Concurrent with the financing, William Dai, founding partner of ShangBay Capital, will join the Corinth MedTech's board of directors.
Additionally, ShangBay Capital is Corinth MedTech's new investor, said president and CEO Csaba Truckai.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial